Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

de sangosse sa - metaldehyde - pellet (eg snail bait) - metaldehyde aldehyde active 50.0 g/kg - molluscicide - agricultural areas - see label | cereal crop | commercial/industrial land | fruit - refer to label | oilseed crops - see label | - slug | small brown snail | snail - see label for exceptions | snail and slug - except brown snails

Europeiska unionen - engelska - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratory syncytial virus infections - vaccines - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older.the use of this vaccine should be in accordance with official recommendations. 

Australien - engelska - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - fluorometholone acetate -

Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

de sangosse sa - metaldehyde - ready-to-use bait - metaldehyde aldehyde active 40.0 g/kg - molluscicide

USA - engelska - NLM (National Library of Medicine)

alcon laboratories, inc. - fluorometholone acetate (unii: 9i50c3i3ok) (fluorometholone - unii:sv0csg527l) - fluorometholone acetate 1 mg in 1 ml - flarex (fluorometholone acetate ophthalmic suspension) is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. contraindicated in acute superficial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases of cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases; acute purulent untreated infections, which like other diseases caused by microorganisms, may be masked or enhanced by the presence of the steroid; and in those persons who have known hypersensitivity to any component of this preparation.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fluorometholone acetate, quantity: 1 mg/ml - eye drops, suspension - excipient ingredients: sodium chloride; tyloxapol; benzalkonium chloride; monobasic sodium phosphate; hyetellose; purified water; hydrochloric acid; sodium hydroxide; disodium edetate - indications as at 21 april 1989: flurometholone acetate ophalmic suspension is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - fluorometholone acetate -

Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

de sangosse sa - metaldehyde - pellet (eg snail bait) - metaldehyde aldehyde active 50.0 g/kg - molluscicide - agricultural areas - see label | cereal crop | commercial/industrial land | fruit - refer to label | oilseed crops - see label | - slug | small brown snail | snail - see label for exceptions | snail and slug - except brown snails

Malta - engelska - Medicines Authority

s.a alcon-couvreur n.v. - fluorometholone acetate 1 mg/ml - eye drops, suspension

USA - engelska - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - recombinant respiratory syncytial virus pre-fusion f protein (unii: m739eb7427) (recombinant respiratory syncytial virus pre-fusion f protein - unii:m739eb7427) - arexvy is indicated for active immunization for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in individuals 60 years of age and older. do not administer arexvy to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of arexvy [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. arexvy is not approved for use in persons <60 years of age. in a clinical study that enrolled pregnant individuals who received an investigational unadjuvanted rsv vaccine that contained the same rsvpref3 antigen as arexvy, an increase in preterm births was observed compared to pregnant individuals who received placebo (sucrose reconstituted with saline). data in a randomized controlled clinical trial that enroll